Phase 4 N=12 Effects of Perampanel on Neurophysiology Test Perimeters
Healthy
Primary: Change in Baseline Visual Evoked Potential (P100) Amplitude
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=170 Short Messaging Service for Optimizing Hemoglobin A1C Management in Low-Income Diabetics
Diabetes
Primary: Change From Baseline A1C — 1.1; 1.4 percentage of A1C decrease
N/A N=3,051 S1204, Viral Screening in Newly Diagnosed Cancer Patients
Cancer
Primary: Number of Participants With Positive Viral Infection — 19; 197; 71; 34 Participants
Phase 1 N=12 Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)
Human Immunodeficiency Virus (HIV) Infection
Primary: Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Islatravir (ISL) in Plasma — 5.81; 7.74 Hours*μmol/Liter
Phase 4 N=33 Erector Spinae Plane vs. Paravertebral Nerve Block for Thoracic Surgery
Thoracic Surgical Procedures
Primary: Total Opioid Consumption — 187.36; 164.70 mg morphine equivalent (MME)
N/A N=30 Investigation of New Intermittent Catheters in Healthy Volunteers
Retention, Urinary
Primary: Residual Urine at 1st Flow-stop — 35.0; 1.1; 0.2; 37.0 mL — p=0.010
Phase 2 N=226 Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
Seborrheic Dermatitis
Primary: Achievement of Investigator Global Assessment (IGA) Success at Week 8 — 104; 27 Participants — p=<0.0001
Phase 2 N=104 Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy
Painful Diabetic Neuropathies
Primary: The Primary Study Endpoint Was the Change in Average 24-hour Pain Score From Baseline to the 6-month Follow-up. — -1.94; -2.78; -1.59 units on a scale
Phase 4 N=62 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders
Obsessive-Compulsive Disorder · Tic Disorders · Tourette Syndrome
Primary: Change in Brain Activation - Insula Cortex — -0.071; -0.0094 Parameter estimate of BOLD Signal Change
Phase 2 N=89 Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC
Advanced Hepatocellular Carcinoma
Primary: Phase Ib: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-treatment Period — 6; 10; 10; 5 Participants
Phase 2 N=18 Niraparib + Dostarlimab + RT in Pancreatic Cancer
Pancreatic Cancer · Metastatic Pancreatic Cancer
Primary: Disease Control Rate With RECIST 1.1 Criteria — 0 Participants
Phase 2 N=31 Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840
Wilson Disease
Primary: Change From Baseline in Liver Cu Concentration at Week 48 (Treatment Period) — 92.8 μg/g — p=0.1002
Phase 3 N=223 Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa
Epidermolysis Bullosa
Primary: Proportion of Patients With First Complete Closure of the EB Target Wound Within 45 Days of Treatment — 45; 33 Participants — p=0.013
N/A N=18 Evaluation of Meal Gesture Dosing in Adults With Type 1 Diabetes
Type 1 Diabetes
Primary: Percentage of Time in Range (Phase 1, Software Release Tag 1.0) — 76.1; 84.3; 65.5; 48 percentage of time
Phase 2 N=110 Evaluation of TTP399 in Patients With Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 — 0.08; -0.60; 0.07; -0.14 percent change — p=<0.0001